ArticleBMC cancer2025
Survival machine learning model of T1 colorectal postoperative recurrence after endoscopic resection and surgical operation: a retrospective cohort study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Pathology-derived clinical micro-architectural diagnostics of tumour-microbiome interactions in colorectal cancer.Journal of translational medicine · 2026Article
- Artificial intelligence models for survival prediction in colorectal cancer: a systematic review of time-to-event approaches.Annals of medicine and surgery (2012) · 2026Article
- A machine learning-based transcriptomic signature for predicting tumor recurrence after curative resection in T1 colorectal cancer: a retrospective multicenter cohort study (The Tw1CE trial).International journal of surgery (London, England) · 2026Article
- Targeting molecular residual disease and immune escape in colorectal cancer recurrence: biomarker-guided immunotherapy and cell therapies.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo construct a postoperative recurrence prediction model for patients with T1 colorectal cancer after endoscopic resection and surgical operation via survival machine learning algorithms.
methodsBased on two tertiary-level affiliated hospitals, case data of 580 patients with T1 colorectal cancer treated by endoscopic resection and surgery were obtained, and patients' personal information, treatment modalities, and pathology-related information were extracted. After Boruta's algorithmic feature selection, predictors with significant contributions were identified. The patients were divided into a train set and a test set at a ratio of 7:3, and five survival machine learning models were subsequently built, namely, Randomized Survival Forest (RSF), Gradient Boosting (GB), Survival Tree (ST), CoxPH and Coxnet. Interpretability analysis of the model is based on the SHAP algorithm.
resultsPatients at high risk of lymph node metastasis have a poor prognosis, but different treatment modalities do not significantly affect the prognosis of patients with recurrence. The Random Survival Forest model shows better performance, with a C-index and Integrated Brier Score of 0.848 and 0.098 in the test set, respectively, and its time-dependent AUC is 0.918. The interpretability analysis of the model revealed that submucosal invasion depth < 1000 μm, tumor budding grade of BD1, lymphovascular invasion and perineural invasion are absent, well differentiated cancer cells, and tumor size < 20 mm have positive effects on the model, lts negative gain characteristics are a contributing factor to patient relapse.
conclusionsThe prognostic model constructed via survival machine learning for patients with T1 colorectal cancer has good performance, and can provide accurate individualized predictions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.